Retained Earnings (Accumulated Deficit) of Y-mAbs Therapeutics, Inc. from 31 Dec 2017 to 30 Jun 2025

Taxonomy & unit
us-gaap: USD
Description
The cumulative amount of the reporting entity's undistributed earnings or deficit.
Summary
Y-mAbs Therapeutics, Inc. quarterly Retained Earnings (Accumulated Deficit) in USD history and change rate from 31 Dec 2017 to 30 Jun 2025.
  • Y-mAbs Therapeutics, Inc. Retained Earnings (Accumulated Deficit) for the quarter ending 30 Jun 2025 was $495,571,000, a 4.7% decline year-over-year.
Source SEC data
View on sec.gov
Retained Earnings (Accumulated Deficit), Quarterly (USD)
Retained Earnings (Accumulated Deficit), YoY Quarterly Change (%)

Y-mAbs Therapeutics, Inc. Quarterly Retained Earnings (Accumulated Deficit) (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q2 2025 $495,571,000 -$22,223,000 -4.7% 30 Jun 2025 10-Q 08 Aug 2025 2025 Q2
Q1 2025 $492,332,000 -$28,233,000 -6.1% 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 $487,136,000 -$29,666,000 -6.5% 31 Dec 2024 10-Q 08 Aug 2025 2025 Q2
Q3 2024 $480,346,000 -$23,864,000 -5.2% 30 Sep 2024 10-Q 08 Nov 2024 2024 Q3
Q2 2024 $473,348,000 -$24,613,000 -5.5% 30 Jun 2024 10-Q 12 Aug 2024 2024 Q2
Q1 2024 $464,099,000 -$21,666,000 -4.9% 31 Mar 2024 10-Q 07 May 2024 2024 Q1
Q4 2023 $457,470,000 -$21,427,000 -4.9% 31 Dec 2023 10-K 04 Mar 2025 2024 FY
Q3 2023 $456,482,000 -$19,282,000 -4.4% 30 Sep 2023 10-Q 13 Nov 2023 2023 Q3
Q2 2023 $448,735,000 -$39,061,000 -9.5% 30 Jun 2023 10-Q 10 Aug 2023 2023 Q2
Q1 2023 $442,433,000 -$73,890,000 -20% 31 Mar 2023 10-Q 08 May 2023 2023 Q1
Q4 2022 $436,043,000 -$95,568,000 -28% 31 Dec 2022 10-K 29 Feb 2024 2023 FY
Q3 2022 $437,200,000 -$133,618,000 -44% 30 Sep 2022 10-Q 07 Nov 2022 2022 Q3
Q2 2022 $409,674,000 -$134,950,000 -49% 30 Jun 2022 10-Q 08 Aug 2022 2021 Q3
Q1 2022 $368,543,000 -$116,756,000 -46% 31 Mar 2022 10-Q 09 May 2022 2022 Q1
Q4 2021 $340,475,000 -$55,275,000 -19% 31 Dec 2021 10-K 30 Mar 2023 2022 FY
Q3 2021 $303,582,000 -$38,315,000 -14% 30 Sep 2021 10-Q 04 Nov 2021 2021 Q3
Q2 2021 $274,724,000 -$42,289,000 -18% 30 Jun 2021 10-Q 09 Aug 2021 2021 Q2
Q1 2021 $251,787,000 -$59,745,000 -31% 31 Mar 2021 10-Q 06 May 2021 2021 Q1
Q4 2020 $285,200,000 -$119,337,000 -72% 31 Dec 2020 10-K 01 Mar 2022 2021 FY
Q3 2020 $265,267,000 -$122,540,000 -86% 30 Sep 2020 10-Q 05 Nov 2020 2020 Q3
Q2 2020 $232,435,000 -$113,630,000 -96% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $192,042,000 -$91,273,000 -91% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $165,863,000 -$81,028,000 -96% 31 Dec 2019 10-K 01 Mar 2021 2020 FY
Q3 2019 $142,727,000 -$71,952,000 -102% 30 Sep 2019 10-Q 13 Nov 2019 2019 Q3
Q2 2019 $118,805,000 30 Jun 2019 10-Q 14 Aug 2019 2019 Q2
Q1 2019 $100,769,000 31 Mar 2019 10-Q 10 May 2019 2019 Q1
Q4 2018 $84,835,000 -$43,274,000 -104% 31 Dec 2018 10-K 12 Mar 2020 2019 FY
Q3 2018 $70,775,000 30 Sep 2018 10-Q 13 Nov 2018 2018 Q3
Q4 2017 $41,561,000 31 Dec 2017 10-K 22 Mar 2019 2018 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.